Aims The objective of the study was to quantify the association between SGLT2 inhibitors
and genital mycotic infection and between SGLT2 inhibitors and urinary tract infection (UTI) …

The extent to which sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors increase the risk of
genital infections in routine clinical care, compared with other antidiabetic medications, is …

Introduction To identify risk factors, absolute risk, and impact on treatment discontinuation of
genital infections with sodium-glucose co-transporter-2 inhibitors (SGLT2i). Research …

Objective To review the incidence, risk factors, prevention, and management of genital
mycotic infections (GMIs) associated with sodium-glucose cotransporter 2 (SGLT2) …

Aims To evaluate the effects of different sodium‐glucose co‐transporter 2 (SGLT2) inhibitors
on the risk of urinary tract infections (UTIs) and genital infections in patients with type 2 …

Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with
sodium–glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings …

Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and
genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 …

Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2
diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are …

Aims There is concern about the infection-related safety profile of sodium–glucose co-
transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on …

Aims To explore the feasibility of MedicineInsight data to support risk management plan
evaluation, focusing on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 …